Menu
Not yet recruiting NCT06772298

Study of Oxidized Albumin in Liver Transplant Patients

Observational Liver Failure Liver Cirrhosis Liver Transplant Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Liver Failure, Liver Cirrhosis, Liver Transplant Disorder. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The overall goal is to describe the oxidation state of albumin before, during and after liver transplantation. This is a pilot observational study in which the oxidative state in 10 patients undergoing liver transplantation will be described. Samples for analysing the oxidation state of albumin, general oxidative damage and anti-oxidant state, the activation of the complement system and factors involved in coagulation will be obtained before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.

Primary outcome measures

  • Albumin quality [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
Secondary outcome measures (9)
  • Effect of clinical factors on albumin quality before transplantation [Time frame: Before transplantation.]
  • Effect of clinical factors on albumin quality after transplantation [Time frame: On postop days 1, 2 and about 30.]
  • Graft outcome in relation to albumin quality [Time frame: At days 1, 2 and about 30 days after transplantation]
  • Oxidative stress in relation to albumin quality [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
  • Anti-oxidant capacity in relation to albumin quality [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
  • Binding capacity [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
  • Complement system [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
  • Complement system [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]
  • Coagulation [Time frame: Before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.]

Eligibility criteria

Inclusion criteria

  • Patients on waiting list for liver transplantation

Exclusion criteria

  • none

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06772298 · K 2024-3904

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗